Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

A Study to Evaluate the Pharmacokinetics of BMS-986177 From Form A and Form B in Healthy Participants

Assess the pharmacokinetics (fasting and fed), safety, and tolerability of BMS-986177 following oral dosing of Form A and Form B

Inclusion Criteria:

• Body mass index 18.0 to 32.0 kg/m2, inclusive
• Women must not be of childbearing potential (cannot become pregnant)

Exclusion Criteria:

• Any significant acute or chronic medical illness
• Head injury in the last 2 years
• History of bleeding disorder including rectal bleeding (ie, hemorrhoids), spontaneous nosebleeds, etc.

Other protocol defined inclusion / exclusion criteria could apply